BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38284208)

  • 1. The impacts of biologic treatment on metabolic profiling in psoriasis.
    Deng S; Zhou G; Li X; Zhang G; Hu K; Lu Y; Li J; Liu Y; Zhou G; Zhang M; Chen J; Liu H; Kuang Y
    Exp Dermatol; 2024 Jan; 33(1):e15011. PubMed ID: 38284208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
    J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis.
    Zeng C; Wen B; Hou G; Lei L; Mei Z; Jia X; Chen X; Zhu W; Li J; Kuang Y; Zeng W; Su J; Liu S; Peng C; Chen X
    Gigascience; 2017 Oct; 6(10):1-11. PubMed ID: 29046044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
    Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
    J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
    Kusakari Y; Yamasaki K; Takahashi T; Tsuchiyama K; Shimada-Omori R; Nasu-Tamabuchi M; Aiba S
    J Dermatol; 2015 Jul; 42(7):727-30. PubMed ID: 25916786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
    Bayaraa B; Imafuku S
    J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
    Papp KA; Lebwohl MG
    J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.